A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China
This is a multi-center, prospective and observational clinical study. Eligible patients will accept generalized chemotherapy according to the investigator's assessment. Information related to the treatment, including medication, disease condition, expenses, etc. will be periodically collected. Follow-up at 2-month intervals will be periodically performed to continually collect information about the disease progression, subsequent treatment and survival until death or completion of the study.
Recruited patients will fill out questionnaires about quality of life before initiation of treatment, at Cycle 3 and completion of first-line treatment.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China|
- chemotherapy regimen [ Time Frame: 2 months ]To evaluate the treatment model (singel or doublet or triplet chemotherapy)of patients with advanced gastric cancer in China
- overall survival [ Time Frame: 2 months ]OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 2 months till death or lost
- quality of life [ Time Frame: 6 weeks ]To evaluate the quality of life before and after chemotherapy of Chinese patients in real clinical practice
- treatment expense [ Time Frame: 2 months ]To evaluate the treatment expense of first-line treatment of Chinese patients with advanced gastric cancer in real clinical practice
Biospecimen Retention: Samples With DNA
|Study Start Date:||November 2011|
|Study Completion Date:||July 2016|
|Primary Completion Date:||July 2016 (Final data collection date for primary outcome measure)|
Eligible patients will accept generalized chemotherapy according to the investigator's assessment.
Drug: Clinical chemo-drugs
Clinical drugs will be selected by the investigator according to recommendations in Chinese and foreign guidelines and depending on clinical experience and the patient's individual conditions, including but not limited to the drugs listed below:
Platinum products: oxaliplatin, cisplatin Fluorouracil products: 5-fluorouracil, capecitabine, TS-1 Taxanes: paclitaxel, docetaxel
Please refer to this study by its ClinicalTrials.gov identifier: NCT01472250
|Beijing, Beijing, China, 100142|